Dr. Thomas is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
100 Buckwalter Place Blvd #130
Bluffton, SC 29910Phone+1 843-836-7101Fax+1 843-836-7112- Is this information wrong?
Education & Training
Wake Forest University Baptist Medical CenterFellowship, Hematology and Medical Oncology, 1993
Medical College of GeorgiaInternship, Internal Medicine, 1990 - 1991- Medical College of GeorgiaResidency, Internal Medicine, 1987 - 1990
Medical University of South CarolinaClass of 1987
Certifications & Licensure
SC State Medical License 1988 - 2025
GA State Medical License 1990 - 2025
NC State Medical License 1991 - 2011- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant Start of enrollment: 2011 Apr 20
- GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC Start of enrollment: 2019 Jan 03
- realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL Start of enrollment: 2021 Sep 20
Roles: Contact
Publications & Presentations
PubMed
- 11 citationsA Phase 2 Study of PCI-27483, a Factor VIIa Inhibitor in Combination with Gemcitabine for Advanced Pancreatic Cancer.Ramesh K. Ramanathan, Gary W. Thomas, Alok A. Khorana, Satish Shah, Cathy Zhou, Sofia Wong, George Cole, Danelle F. James, Nashat Y. Gabrail> ;Oncology. 2019 Jan 1
- 364 citationsNeratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3..., , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,...> ;The Lancet. Oncology. 2017 Dec 1
- 48 citationsImatinib Mesylate Inhibits Platelet-Derived Growth Factor Receptor Phosphorylation of Melanoma Cells but Does Not Affect Tumorigenicity in VivoEric C. McGary, Amir Onn, Lisa Mills, Amy B. Heimberger, Omar Eton, Gary W. Thomas, Mikhail Shtivelband, Menashe Bar-Eli> ;The Journal of Investigative Dermatology. 2004 Feb 1
- Join now to see all
Press Mentions
Trump Breaks the Quarantine, Works in His Office and Says That Getting Infected Was a Blessing from GodOctober 8th, 2020
Hilton Head Hires: OCTOBER 2019September 27th, 2019
Hilton Head Cancer Patients Get a Special Delivery of Warmth and HopeJuly 6th, 2017
Professional Memberships
- South Carolina Oncology SocietyExecutive Board Member
Hospital Affiliations
- Hilton Head HospitalHilton Head Island, South Carolina
Candler HospitalSavannah, Georgia
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
